These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20950732)

  • 1. Imatinib treatment of generalized localized scleroderma (morphea).
    Moinzadeh P; Krieg T; Hunzelmann N
    J Am Acad Dermatol; 2010 Nov; 63(5):e102-4. PubMed ID: 20950732
    [No Abstract]   [Full Text] [Related]  

  • 2. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
    de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
    Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate.
    Inamo Y; Ochiai T
    Pediatr Dermatol; 2013; 30(6):e191-3. PubMed ID: 23025697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib treatment of therapy resistant generalized deep morphea.
    Alcántara-Reifs CM; Garnacho-Saucedo GM; Salido-Vallejo R; de la Corte-Sánchez S; García-Nieto AV
    Dermatol Ther; 2015; 28(5):271-3. PubMed ID: 26032018
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib: a novel treatment approach for generalized morphea.
    Coelho-Macias V; Mendes-Bastos P; Assis-Pacheco F; Cardoso J
    Int J Dermatol; 2014 Oct; 53(10):1299-302. PubMed ID: 24697802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
    Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
    Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
    [No Abstract]   [Full Text] [Related]  

  • 7. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y; Gottlieb AB
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
    Taïeb A; Constans J; Mahon FX
    Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
    [No Abstract]   [Full Text] [Related]  

  • 9. MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate.
    Warakaulle DR; Gleeson F
    AJR Am J Roentgenol; 2006 Feb; 186(2):510-5. PubMed ID: 16423961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
    ten Freyhaus H; Dumitrescu D; Bovenschulte H; Erdmann E; Rosenkranz S
    Clin Res Cardiol; 2009 Apr; 98(4):265-7. PubMed ID: 19219392
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib mesylate induces clinical remission in rheumatoid arthritis.
    Pereira I; Fialho S; Castro G; Zimmermann A
    Joint Bone Spine; 2010 Jul; 77(4):372-3. PubMed ID: 20478730
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib for the treatment of rheumatic diseases.
    Paniagua RT; Robinson WH
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):190-1. PubMed ID: 17396105
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
    Sanford M; Scott LJ
    BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
    [No Abstract]   [Full Text] [Related]  

  • 15. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
    Mendoza FA; Jiménez SA
    Arthritis Rheum; 2011 Nov; 63(11):3199-203. PubMed ID: 21769846
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?
    Erre GL; Pardini S; Cuccuru L; Taras L; Passiu G
    Joint Bone Spine; 2015 Jan; 82(1):72-3. PubMed ID: 25059880
    [No Abstract]   [Full Text] [Related]  

  • 17. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
    Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there a role for imatinib in inflammatory bowel disease?
    De Backer O; Lefebvre RA
    Inflamm Bowel Dis; 2008 Apr; 14(4):579-81. PubMed ID: 18050299
    [No Abstract]   [Full Text] [Related]  

  • 19. Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?
    Sfikakis PP
    Clin Immunol; 2011 Dec; 141(3):240-1. PubMed ID: 21996458
    [No Abstract]   [Full Text] [Related]  

  • 20. Current management of GISTs.
    Blanke C
    Clin Adv Hematol Oncol; 2010 May; 8(5):334. PubMed ID: 20551892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.